| Carcinoma breast stage IV
Verzenio vs Orserdu
Side-by-side clinical, coverage, and cost comparison for carcinoma breast stage iv.Deep comparison between: Verzenio vs Orserdu with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOrserdu has a higher rate of injection site reactions vs Verzenio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Orserdu but not Verzenio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Verzenio
Orserdu
At A Glance
Oral
Twice daily
CDK4/6 inhibitor
Oral
Daily
Estrogen receptor antagonist
Indications
- Malignant neoplasm of breast
- Carcinoma breast stage IV
- Carcinoma breast stage IV
Dosing
Malignant neoplasm of breast 150 mg orally twice daily in combination with tamoxifen or an aromatase inhibitor for 2 years as adjuvant treatment (or until disease recurrence or unacceptable toxicity).
Carcinoma breast stage IV 150 mg orally twice daily in combination with an aromatase inhibitor (initial therapy) or fulvestrant (after endocrine therapy progression); 200 mg orally twice daily as monotherapy (after endocrine therapy and prior chemotherapy); continue until disease progression or unacceptable toxicity.
Carcinoma breast stage IV 345 mg taken orally once daily with food until disease progression or unacceptable toxicity; dose reductions to 258 mg or 172 mg once daily for adverse reactions.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, thrombocytopenia
Serious neutropenia, diarrhea, interstitial lung disease/pneumonitis, hepatotoxicity, venous thromboembolism
Postmarketing interstitial lung disease/pneumonitis
Most common (>=10%) Musculoskeletal pain, nausea, increased cholesterol, increased AST, increased triglycerides, fatigue, decreased hemoglobin, vomiting, increased ALT, decreased sodium, increased creatinine, decreased appetite, diarrhea, headache, constipation, abdominal pain, hot flush, dyspepsia.
Serious Musculoskeletal pain, nausea.
Pharmacology
Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6); in ER-positive breast cancer cells, it blocks Rb phosphorylation and cell cycle progression from G1 into S phase, resulting in senescence and apoptosis.
Estrogen receptor antagonist that binds to ERalpha and inhibits 17beta-estradiol mediated cell proliferation through ERalpha protein degradation via the proteasomal pathway, with demonstrated antitumor activity in ESR1-mutated and CDK4/6 inhibitor-resistant ER+ HER2- breast cancer models.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Verzenio
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Orserdu
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Verzenio
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Orserdu
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Verzenio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Orserdu
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
VerzenioView full Verzenio profile
OrserduView full Orserdu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.